LONGEVITY & CELLULAR HEALTH / COLOPHON
About This Desk
A citation-anchored survey of the longevity-research literature. Nothing sold here, no clinic, no dose to copy.
What Supernova Peptides is
Supernova Peptides charts the published research on three agents studied at the intersection of longevity and cellular health — Epitalon, MOTS-c, and NAD+, with Epitalon in the lead. The site exists to make a scattered, technically demanding, and frequently overstated literature legible — to tell a reader, in plain language and with citations, what each agent was actually studied on, in which species or model, and how far that evidence really reaches.
The organizing idea is an aging-biology frame: three compounds that approach cellular aging from complementary directions — telomere maintenance and neuroendocrine regulation (Epitalon), mitochondrial stress signaling (MOTS-c), and coenzyme substrate replenishment (NAD+) — so that reading them together gives a more complete picture than any single compound page alone. Each compound has its own research page; a comparison page lines them up side by side; and a shared references list aggregates every source.
This is an observation log, not a guide to use. It sells no compound, offers no medical guidance, recommends no dose or protocol, and endorses no particular source, supplier, or clinic.
Editorial method
Every factual claim on this site is grounded in a peer-reviewed publication or registered clinical trial, cited by number and linked to PubMed, a journal DOI, or ClinicalTrials.gov. The references list at the bottom of this site aggregates all sources cited across all pages.
Literature is selected by relevance to the compound and the aging-biology frame, by publication quality (peer-reviewed journals, systematic reviews, and RCTs weighted more heavily than conference abstracts or in vitro studies without follow-up), and by recency where the field has moved. Where evidence is thin, preliminary, single-lab, or preclinical only, this desk says so explicitly — qualifying statements like "in mice," "observational only," "not randomized," and "no human trials" are part of the factual record, not hedging.
One source-concentration issue is handled explicitly: Epitalon's evidence base is weighted heavily toward a single Russian research program. This desk reports those studies faithfully, flags the source concentration wherever relevant, and notes when and where independent replication has or has not occurred. That transparency is part of what makes this desk useful — a reader should be able to see where the evidence is solid and where it is narrowly sourced.
Independence and disclaimer
Supernova Peptides keeps an observation log and nothing more. It has no commercial relationship with any manufacturer, supplier, clinic, or practitioner of the compounds discussed. No product is promoted, no service is endorsed, and no affiliate revenue flows from this site.
What you read here is a synthesis of the peer-reviewed literature — a mapping of what has been published — and explicitly not medical advice, clinical guidance, or a recommendation to use any compound. None of the agents covered (Epitalon, MOTS-c) are approved for human use in the US, EU, or UK. NAD+ and its precursors (NMN, NR) are sold as dietary supplements; they are not approved drugs and the research summarized here does not constitute a recommendation to take them.
If you are considering any compound discussed on this site, consult a qualified healthcare provider with access to your individual medical history. This desk is a starting point for understanding the research — not a substitute for professional medical judgment.